Related Experiment Videos
Aortic leaflet replacement with the new 3F stentless aortic bioprosthesis
Mirko Doss1, Sven Martens, Jeffrey P Wood
1Department of Thoracic and Cardiovascular Surgery, Johann Wolfgang Goethe University, Frankfurt/Main, Germany. mirkodoss@aol.com
The Annals of Thoracic Surgery
|February 1, 2005
Summary
The 3F stentless aortic bioprosthesis demonstrates excellent hemodynamic performance in patients, comparable to traditional stentless valves. Its unique design simplifies surgical implantation, offering a promising alternative for aortic valve replacement.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Heart Valve Replacement
Background:
- The 3F aortic bioprosthesis is a novel stentless biological heart valve.
- It is constructed from equine pericardium in a unique tubular design.
- This valve is designed for implantation in the native aortic root.
Purpose of the Study:
- To present initial clinical experiences with the 3F stentless aortic bioprosthesis.
- To evaluate the early performance of this new aortic bioprosthesis.
- To assess the feasibility and outcomes of its implantation.
Main Methods:
- Twenty-four 3F aortic bioprostheses were implanted between January 2002 and August 2002.
- Echocardiography was used to assess hemodynamic parameters.
- Evaluations included effective orifice area, mean gradients, and ejection fraction at discharge and 12-month follow-up.
Main Results:
- At 12-month follow-up, significant hemodynamic improvements were observed.
- Mean aortic valve gradients decreased to 10.3 mm Hg.
- Mean effective orifice area was 1.7 cm², and mean ejection fraction was 61.5%.
Conclusions:
- The 3F aortic bioprosthesis exhibits clinical performance comparable to existing stentless aortic valves.
- Its unique design offers advantages in surgical implantation ease.
- This device represents a viable option for aortic valve replacement procedures.